Treatment and outcomes for primary cutaneous extramedullary plasmacytoma: a case series

Case Report

Treatment and outcomes for primary cutaneous extramedullary plasmacytoma: a case series

D.S. Tsang, MD*, L.W. Le, MSc, V. Kukreti, MD, A. Sun, MD*




Primary cutaneous plasmacytoma (pcp) is a rare disease, with few studies to guide therapy. Our primary study objective was to define treatments used for pcp; a secondary objective was to describe outcomes of patients, including disease recurrence and death.


An institutional cancer registry was used to identify cases for retrospective chart review. In a systematic review, treatments for, and outcomes of, all known cases of pcp were described.


Three eligible cases identified at our institution; each patient had a solitary pcp. The systematic review identified 66 patients. Radiotherapy was the most commonly used primary treatment modality (31% of all patients; 42% for patients with solitary lesions), followed by surgery (28% of all patients; 36% for patients with solitary lesions). Median survival for all patients was 10.4 years [95% ci: 4.3 years to not reached], with a trend toward a decreased risk of death with solitary lesions compared with multiple lesions (hazard ratio: 0.37; 95% ci: 0.13 to 1.08; p = 0.059). For patients with solitary lesions, the median and recurrence-free survivals were, respectively, 17.0 years (95% ci: 1.7 years to not reached) and 11.0 years (95% ci: 2 years to not reached); for patients with multiple lesions, they were 4.3 years (95% ci: 1.3 to not reached) and 1.4 years (95% ci: 0.6 years to not reached). Disease recurrence, including progression to multiple myeloma, was the most common cause of death.


Compared with patients having multiple pcp lesions, those presenting with a single pcp lesion might experience longer overall survival. Local therapy (radiation or surgery) is a reasonable curative treatment for a solitary pcp lesion.

KEYWORDS: Chemotherapy, plasmacytoma, radiotherapy, skin, surgery


Primary cutaneous plasmacytoma (pcp) is a rare diagnosis, with fewer than 50 cases estimated to be have been reported and compiled in the literature13. Cutaneous deposits of plasma cells are more commonly seen in the context of multiple myeloma, where such deposits are associated with poor prognosis4,5. However, because of good long-term outcomes, treatment for plasmacytoma is typically approached with curative intent; for solitary lesions, local treatments such as radiotherapy (rt) or surgery play an important role6. As well, compared with osseous plasmacytomas, soft-tissue plasmacytomas are associated with a lower rate of progression to multiple myeloma7. Plasmacytoma of the integumentary system (a non-osseous organ) is classified as an extramedullary plasmacytoma.

Because of pcp’s rarity, little is known about its treatment, which can vary widely, ranging from surgical excision to systemic therapy and rt1,2. Furthermore, details of treatment are poorly described; many case reports focus only on the pathologic diagnosis3,811. Although extramedullary plasmacytomas are associated with good clinical outcomes, patients with pcp can develop local recurrence, distant skin recurrence, or systemic progression to multiple myeloma1,2. Some authors have suggested an association with improved clinical outcomes in patients with a solitary pcp lesion compared with multiple pcp lesions1,1214.

Because pcp is a rare disease, information to guide therapy is limited. In the present study, a retrospective chart review considered cancer registry data for all patients seen at a single institution. A systematic review of the literature provided further information about treatments and outcomes in pcp.


Chart Review

In our single-institution retrospective chart review, patients with a single pcp lesion or multiple pcp lesions were included. Patients were excluded if they had synchronous involvement of bone, bone marrow, or lymph nodes; multiple myeloma at diagnosis of pcp; cutaneous manifestation of multiple myeloma; diagnosis of post-transplant lymphoproliferative disorder; poems syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes); aesop (adenopathy and extensive skin patch overlying a plasmacytoma); infectious or reactive causation (for example, insect bite or herpes simplex virus); or polyclonal plasma cell infiltrates. Patients were identified using the Princess Margaret Cancer Registry, which includes all patients with malignancy seen or treated at the Princess Margaret Cancer Centre dating back to 1958. Charts of identified patients were then reviewed to extract clinical details, pathology, treatment, response to therapy, follow-up, and vital status.

The primary objective of our study was to describe treatments used for pcp. Secondary objectives were to describe recurrence-free survival (rfs) and overall survival (os) in patients with pcp. The study was reviewed and approved by the University Health Network Research Ethics Board.

Systematic Review

In the systematic review, published articles were included if they described one or more patients with pcp. The inclusion and exclusion criteria were the same as those used in the chart review. No language restrictions were applied. A database search of medline (1946–2015) was performed on 10 April 2015 using the search terms “exp Plasmacytoma/ and and exp Skin/ or exp Skin Neoplasms/ or exp Carcinoma, Skin Appendage/ or or exp Skin Diseases/” and was limited to “humans” and “cancer.” Full article texts were reviewed; if the text was unavailable, the article title and abstract was reviewed. Reference lists were screened for additional articles. Patient details (diagnosis, number of skin lesions, treatment, recurrence, vital status, and follow-up if available) were extracted from published articles and entered into a standardized data collection form. Cases were classified as “solitary” if the patient had an isolated single cutaneous plasmacytoma, with no other cutaneous or soft-tissue or osseous lesions; otherwise, the case was classified as “multiple.” Pathologic diagnosis and histology were not a focus of this systematic review.


The rfs was defined as time from pathologic diagnosis of the index lesion to recurrence or progression of plasmacytoma, development of multiple myeloma, or death. Persistent disease after treatment was counted as a recurrence at time of treatment. The os was defined as time from pathologic diagnosis of the index lesion to death. Patients lost to follow-up were censored. Kaplan–Meier curves were constructed for rfs and os. Univariate hazard ratios with 95% confidence intervals (cis) were calculated using a Cox proportional hazards model. All statistical analyses were performed using the SAS (version 9.4: SAS Institute, Cary, NC, U.S.A.) and R (version 3.2.2: The R Foundation, Vienna, Austria) software applications.


Chart Review

For the 3 eligible patients identified from the cancer registry (Table i), median age was 48 years (range: 48–69 years). Each patient had a solitary pcp. One patient received surgery followed by adjuvant rt; the other two patients received definitive rt alone.

TABLE I Clinical information and diagnostic investigations for three Princess Margaret Cancer Centre patients


Patient 1

A 48-year-old man presented in May 1979 with a single lesion over the right scapula that had doubled in size since March. No constitutional symptoms were reported. The patient had a non-contributory past medical history, but was a heavy smoker and drinker. The subcutaneous tumour was surgically removed by wide local excision on 9 May 1979. The biopsy was signed out as a “malignant plasmacytoma with infiltration of skin and subcutaneous adipose tissue from back,” with negative margins.

Diagnostic investigations were negative for multiple myeloma, with no Bence Jones protein in urine, and normal calcium (exact value not available), albumin (45 g/L), total protein (exact value not available), creatinine [1.0 mgm% (88 mmol/L)], and hemoglobin (141 g/L). Serum protein electrophoresis noted a very small kappa immunoglobulin G component before surgery. Bone marrow biopsy and skeletal survey were normal.

Adjuvant rt was recommended to reduce the risk of local recurrence. A total of 20 Gy in 5 daily fractions using a 250 kVp orthovoltage beam was prescribed [1.1 mm Cu hvl (copper half-value layer), 1 field; Figure 1(A)]. Radiation was completed on 15 June 1979.



FIGURE 1 (A) Radiotherapy field for patient 1. (B) Radiotherapy field for patient 2 (dark circle represents a pencil eye-shield).

The patient experienced a complete clinical response to surgery and adjuvant rt. No recurrence of pcp or multiple myeloma was noted. During a hospital admission in 2000 for congestive heart failure, stroke, pneumonia, and atrial flutter, this patient was found to have an incidental 2×3.8-cm anterior mediastinal mass. The lesion was clinically and radiologically consistent with a thymoma; no biopsy was taken, and the mass was observed. A benign right parotid Warthin tumour was excised in 2001. The patient died of right hemorrhagic stroke on 20 May 2002, 276 months after the initial pcp diagnosis.

Patient 2

A 48-year-old woman presented in March 1983 with a solitary right upper eyelid mass in the skin. Past medical history was non-contributory. Computed tomography of the orbit demonstrated a soft-tissue mass in the right upper eyelid with no bony erosion. A biopsy on 20 July 1983 demonstrated malignant plasmacytoma. The specimen was signed out as “plasma cell tumour,” with monoclonal lambda immunoglobulin A expression.

Diagnostic investigations were negative for multiple myeloma, with no Bence Jones protein in urine, and normal serum calcium, albumin, total protein, creatinine (exact values not available), and hemoglobin (143 g/L). Serum protein electrophoresis did note a lambda immunoglobulin A spike; no bone marrow biopsy was obtained, however. Skeletal survey was normal.

Definitive rt was recommended, to a total dose of 25 Gy in 10 daily fractions, using cobalt-60 external-beam rt. Treatment was delivered using a single anterior field encompassing the right orbit, with a pencil eye shield to block the anterior chamber [Figure 1(B)]. Radiation was completed on 19 August 1983.

During follow-up, the patient experienced complete clinical response of the right eyelid lesion. Normal extra-ocular movements were noted, with no scarring over the eyelid; however, grade 1 dry eye was documented in 1989. Serum immunoglobulin G (normal range: 5–16 g/L) rose from 14 g/L (1986) to 21 g/L (1988) and to 24 g/L (1990). The patient remained asymptomatic, with normal complete blood count, calcium, and albumin. No bone marrow biopsies were obtained. The patient was lost to follow-up after last contact on 17 July 1991, 96 months after initial diagnosis.

Patient 3

A 69-year-old man presented in November 2014 with a solitary 4.5×1.5-cm cutaneous lesion on the left lateral thoracic wall [Figure 2(A)]. The patient had no myalgia, bone pain, or constipation; he had a Zubrod performance score of 0. A prior history of coronary artery disease and asthma was documented. A biopsy on 15 December 2014 showed “dense lymphoplasmacytic infiltrate.” No immunohistochemistry staining was done. A repeat biopsy on 13 January 2015 showed “monotypic plasma cell infiltrate” positive for CD138 and kappa immunoglobulin G, with “only few cells positive for lambda.”



FIGURE 2 Clinical photographs for patient 3. (A) After biopsy, but before treatment (dots surrounding the lesion are clinical mark-up for the orthovoltage field edge). (B) Two months after completion of radiotherapy. Mild hyperpigmentation and erythema are noted. (C) Eight months after completion of radiotherapy.

Diagnostic investigations in February 2015 were negative for multiple myeloma, with no Bence Jones protein in urine, and normal calcium [2.38 mmol/L (normal range: 2.20–2.62 mmol/L)], albumin [39 g/L (normal range: 38–50 g/L)], creatinine [74 μmol/L (normal range: ≤109 μmol/L)], and hemoglobin [158 g/L (normal range: 148–180 g/L)]. Serum protein electrophoresis did not reveal any monoclonal protein spike; β2-microglobulin was 2.9 mg/L (normal range: 0.6–2.3 mg/L), and the free kappa/ lambda ratio was 1.38 (normal range: 0.26–1.65). Bone marrow biopsy was normal, with less than 5% plasma cells; no clonal restriction was observed, although incidental megakaryocytic thrombocytopenia was noted. Computed tomography imaging showed no lymphadenopathy or lytic lesions; skeletal survey showed no lytic lesions.

The patient received definitive rt to 35 Gy in 10 daily fractions delivered using orthovoltage X-rays (225 kVp). Radiation was completed on 21 April 2015. At follow-up in June and December 2015, hyperpigmentation of the skin surrounding the lesion was noted, with complete clinical response and residual scar in the area of the biopsy [Figure 2(B,C)]. Lab work was normal. The patient remains alive and well 11 months after initial diagnosis.

Systematic Review

The systematic review of the literature (Figure 3) identified 66 eligible cases of pcp. Including the 3 patients from our chart review, 69 patients—35 of whom had a solitary pcp lesion—were analyzed (Table ii). Table iii lists the characteristics of those patients. Median follow-up duration was 2 years.



FIGURE 3 Flow diagram of articles and patients included in the systematic review. POEMS = polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes; AESOP = adenopathy and extensive skin patch overlying a plasmacytoma.

TABLE II Summary of all known cases of primary cutaneous plasmacytoma


TABLE III Demographics and clinical characteristics of all patients with primary cutaneous plasmacytoma


Table iv provides rt and chemotherapy details. The rt dose was specified for 15 of the 27 patients (56%) who received rt as a component of their pcp treatment. Three patients received palliative-intent rt (total dose: ≤20 Gy). Two patients received surgery and adjuvant radiation as primary treatment: the dose for one patient was unknown17, and it was 20 Gy in 5 fractions for the other (patient 1 in the present report). One patient received 50 Gy in 25 fractions to a left cheek primary, with no response; salvage surgery was subsequently performed32. As with radiation doses, chemotherapy regimens ranged widely; the most commonly used regimen was melphalan combined with a corticosteroid.

TABLE IV Treatments for primary cutaneous plasmacytoma


Of the patients with a known disease response to chemotherapy or rt, most experienced a complete clinical response (Table v). Of patients with known recurrence details, most had no disease recurrence (Table vi). Among patients with a solitary pcp, 9 recurrences were observed. Local recurrences in 2 patients were both initially treated with surgery23,31. Distant skin recurrences in 5 patients were initially treated with surgery alone32, surgery and rt17, rt alone (2 patients)2,64, or chemotherapy alone45. Finally, 2 patients experienced a distant recurrence; those patients were initially treated with rt44 or observation58. Among the 19 patients for whom information about time-to-recurrence was available, median time to recurrence was 7.0 months (range: 1–132 months), and mean time to recurrence was 17.4 months.

TABLE V Treatments given for primary cutaneous plasmacytoma and responses to treatment


TABLE VI Recurrences and causes of death


Among the 69 analyzed patients, 27 events (recurrence of plasmacytoma, development of multiple myeloma, or death) were reported (Figure 4). Median rfs was 2.7 years (95% ci: 1.4 years to not reached), with 1-year, 2-year, and 5-year rfs estimates of 63%, 53%, and 44% respectively. Of those 27 events, 11 were observed in patients with a solitary pcp, with a median rfs of 11.0 years (95% ci: 2 years to not reached). The other 16 events were seen in patients with multiple lesions, with a median rfs of 1.4 years (95% ci: 0.6 years to not reached). The hazard ratio for rfs for patients with a solitary pcp lesion compared with those having multiple lesions was 0.47 (95% ci: 0.21 to 1.08; p = 0.069). No other variables were associated with rfs or os on univariate analysis (Table vii).



FIGURE 4 Kaplan–Meier curves for (A) all patients, (B) recurrence-free survival (RFS), and (C) overall survival (OS). Open circles represent censored patients.

TABLE VII Univariate Cox proportional hazards analyses of variables associated with recurrence-free survival and overall survival in patients with primary cutaneous plasmacytoma (pCP)


Among the 19 patient deaths reported, 18 had a documented time from diagnosis to death (Figure 4). The remaining patient was censored at last known follow-up51. Median os was 10.4 years (95% ci: 4.3 years to not reached), with 1-year, 2-year, and 5-year os estimates of 80%, 64%, and 59% respectively. In patients with a solitary pcp, 7 deaths were observed, with a median os of 17.0 years (95% ci: 1.7 years to not reached). In patients with multiple pcp lesions, 12 deaths were observed, with a median os of 4.3 years (95% ci: 1.3 years to not reached). The hazard ratio for os in patients with a solitary pcp lesion compared with those having multiple lesions was 0.37 (95% ci: 0.13 to 1.08; p = 0.059).

Table vi reports causes of death. Multiple myeloma was the most common cause of death, followed by recurrent plasma cell disease not meeting diagnostic criteria for multiple myeloma.


The present study represents the largest published single-institution case series of solitary pcp, comprising 3 cases in total. Yamamoto described 3 patients with multiple pcp lesions52. Three other articles have each described 2 patients with pcp2,46,54. Cases of reactive pcp, which are excluded from the present analysis, have also been reported, associated with stimulation from infectious agents such as herpes simplex virus or insect bites67,68.

The present systematic review summarizes all published nonreactive cases of pcp. The most recent comprehensive literature reviews of pcp were published by Muscardin et al.1 in 2000 and Kazakov et al.2 in 2002. Since those reviews, 14 new cases have been published, which are included here. With those cases, analyses of rfs and os were possible (Figure 4), although the data are limited by short follow-up and a small sample size.

As in the present analysis, earlier reviews of patients with pcp have reported a mean age of 60, with male predominance1,2,31. The lesions are often described as reddish or purple nodules or plaques without ulceration2,12,31. The most consistently reported prognostic factor is the number of lesions, with outcomes being better with solitary lesions than with multiple lesions at presentation1,1214. Solitary lesions tended to have less locoregional or distant dissemination and remained confined to the skin1,31; however, large solitary lesions might have a higher risk of progression to metastatic disease (although a size cut-off is not defined)1. Patients with multiple lesions had a higher likelihood of progression to multiple myeloma and subsequent death2,46,68. Muscardin et al.1 did not report any association of paraproteinemia with outcome. The present study accords with the prior finding that paraproteinemia is not associated with survival, although information about other variables associated with progression to multiple myeloma such as immunoglobulin levels or serum free light-chain ratio were not available.

Treatment of pcp should be individualized to the patient and tumour characteristics. In general, authors agreed that curative-intent local treatment—which can entail surgery, rt, or surgery followed by adjuvant rt—is appropriate for solitary pcp lesions1,9,23,31,46. Green et al.68 cautioned that local recurrence or lymph node metastases could develop after local therapy. Patients with multiple pcp lesions are optimally treated with systemic chemotherapy9.

In the present analysis, it was not possible, because the wide range of dose and fractionations used, to draw conclusions about the efficacy of a specific rt dose. Recurrence data and site of recurrence were available but challenging to interpret because of the many patients whose recurrence status was unknown. Nonetheless, it is notable that the only local recurrences observed in patients with a solitary pcp lesion happened in patients initially treated with surgery alone.

The only clinical variable associated with rfs and os was the number of lesions (solitary vs. multiple), which showed a trend toward statistical significance. We observed a large difference in median survival (17 years vs. 4.3 years) and rfs (11.0 years vs. 1.4 years) between patients with solitary lesions and those with multiple lesions, albeit with overlapping cis. Based on those data, patients with solitary lesions are likely to have better outcomes, although that probability cannot be demonstrated to a p value of less than 0.05 because of the small number of events and the lack of long-term follow-up. Therapeutic approach (surgery vs. rt vs. chemotherapy) was not associated with rfs or os; however, our study was underpowered to detect a difference between treatments in the overall study population or in subgroups of patients with solitary or multiple lesions.

The present study contributes to the literature by describing 3 additional patients with a solitary pcp (2 of whom have long-term follow-up) and by updating the systematic review of a rare disease to 69 total cases. However, the analysis is limited by the retrospective collection of published data and the extraction of details from articles. Given the elapsed time, contacting authors directly for further clinical data was infeasible. Epidermal and dermal involvement could not be distinguished. It is also possible that benign plasmacytoses were included in the analysis because information about monoclonality was not available for all reported cases; that limitation is acknowledged by Muscardin et al.1 in their earlier review. Indeed, 3 of the historical patients in the review15,16,18 could potentially have had benign tumours with plasma cell infiltrates or plasmacytic granulomas23,26,31,32,49,68; diagnosis requires careful histologic and immunohistochemical analysis9. Exclusion of the former 3 patients does not change the survival analysis, because follow-up for them was unavailable.

The results of this systematic review are subject to publication bias. A future approach could involve the use of population-level databases to provide accurate information about survival, but granularity of clinical data and treatment details is often unavailable with such an approach.


Primary cutaneous plasmacytoma is a rare diagnosis, with limited information to guide treatment. Here, 3 patients with a solitary pcp lesion are reported, with complete details about treatment. With the accompanying systematic review, a total of 69 patients with pcp are now reported in the literature. Most patients with a solitary pcp received rt as a component of treatment. A trend toward improved median rfs (11 years vs. 1.4 years) and os (17 years vs. 4.3 years) was observed in patients with a solitary pcp compared with those having multiple pcp lesions. Local treatment (such as rt or surgery) should be considered for patients with a solitary pcp; patients with multiple pcp lesions are likely to be best served by systemic chemotherapy. Treatment of pcp should be individualized depending on factors such as patient performance status, lesion count (solitary vs. multiple), and expected ability to tolerate treatment.


The authors thank the Princess Margaret Cancer Registry (Darlene Dale and Krystyna Tybinkowski) for assistance with data inquiries and the Department of Radiation Oncology Academic Enrichment Fund for support.


We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare that we have none.


*Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, and Department of Radiation Oncology, University of Toronto;,
Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network; and,
Division of Hematology/Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON..


1. Muscardin LM, Pulsoni A, Cerroni L. Primary cutaneous plasmacytoma: report of a case with review of the literature. J Am Acad Dermatol 2000;43:962–5.
cross-ref  pubmed  

2. Kazakov DV, Belousova IE, Muller B, et al. Primary cutaneous plasmacytoma: a clinicopathological study of two cases with a long-term follow-up and review of the literature. J Cutan Pathol 2002;29:244–8.
cross-ref  pubmed  

3. Comfere NI, Gonzalez Santiago TM, Peters MS, Knudson RA, Ketterling RP, Gibson LE. Cutaneous extramedullary plasmacytoma: clinical, prognostic, and interphase cytogenetic analysis. Am J Dermatopathol 2013;35:357–63.

4. Kois JM, Sexton FM, Lookingbill DP. Cutaneous manifestations of multiple myeloma. Arch Dermatol 1991;127:69–74.
cross-ref  pubmed  

5. Requena L, Kutzner H, Palmedo G, et al. Cutaneous involvement in multiple myeloma: a clinicopathologic, immunohistochemical, and cytogenetic study of 8 cases. Arch Dermatol 2003;139:475–86.
cross-ref  pubmed  

6. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys 2001;50:113–20.
cross-ref  pubmed  

7. Weber DM. Solitary bone and extramedullary plasmacytoma. Hematology Am Soc Hematol Educ Program 2005;2005:328–6.

8. Maejima H, Katsuoka K, Togano T. Multiple primary cutaneous plasmacytoma. Acta Dermatovenerol Croat 2014;22:308–10.

9. Koletsa T, Patsatsi A, Kostopoulos I, Kartsios C, Korantzis I, Sotiriadis D. A case of a primary cutaneous plasmacytoma presenting in adolescence. Am J Dermatopathol 2012;34:537–40.
cross-ref  pubmed  

10. Fitzhugh VA, Siegel D, Bhattacharyya PK. Multiple primary cutaneous plasmacytomas. J Clin Pathol 2008;61:782–3.
cross-ref  pubmed  

11. Donner LR. Epstein–Barr virus–induced transformation of cutaneous plasmacytoma into CD30+ diffuse large B-cell lymphoma. Am J Dermatopathol 2004;26:63–6.
cross-ref  pubmed  

12. Kerl H, Cerroni L. Primary B-cell lymphomas of the skin. Ann Oncol 1997;8(suppl 2):29–32.
cross-ref  pubmed  

13. Shah A, Klimo P, Worth A. Multiple myeloma first observed as multiple cutaneous plasmacytomas. Arch Dermatol 1982;118:922–4.
cross-ref  pubmed  

14. Stankler L, Davidson JF. Multiple extra-medullary plasmacytomas of the skin. Case report with a note on prognosis. Br J Dermatol 1974;90:217–21.
cross-ref  pubmed  

15. Hedinger E. On the question of plasmacytomas [German]. Frankf Z Pathol 1911;7:343–50.

16. Volk R. Plasmacytoma localized to skin [German]. Wien Med Wochenschr 1936;86:720–1.

17. Frerichs JB, Stout AP. Plasmacytoma of the inframammary region. Mo Med 1949;46:275–7.

18. Agarwal SC. Extramedullary plasmacytoma: report of a case. AMA Arch Derm 1956;74:679–80.
cross-ref  pubmed  

19. Duverne J, Prunieras M, Bonnayme R, Volle H. An unusual malignant cutaneous plasmacytoma [French]. Bull Soc Fr Dermatol Syphiligr 1958;65:132–5.

20. Krutsay M. Solitary plasmacytoma of the skin. Oncologia 1959;12:227–32.
cross-ref  pubmed  

21. Artese D, Matteucci L. On a case of solitary extramedullary plasmacytoma (anatomo-clinical observation) [Italian]. Pathologica 1960;52:263–75.

22. Prost C, Reyes F, Wechsler J, Gaston A, Richard I, Poirier J. High-grade malignant cutaneous plasmacytoma metastatic to the central nervous system. A case report with electron microscopy, immunohistological, and neuropathological studies. Am J Dermatopathol 1987;9:30–6.
cross-ref  pubmed  

23. Johnson WH Jr, Taylor BG. Solitary extramedullary plasmacytoma of the skin. A review of the world literature and the report of an additional case. Cancer 1970;26:65–8.
cross-ref  pubmed  

24. Sicard D, Clauvel JP, Dugelay F, Verliac F, Bastin R. Multiple subcutaneous plasmocytosarcoma (1 case) [French]. Sem Hop 1970;46:1954–9.

25. Pianzola L, Casteletto R, Drut R. Extramedullary primary cutaneous plasmacytoma (plasmacytoma cutis) with monoclonal IgA gammopathy [Spanish]. Med Cutan Ibero Lat Am 1972;6:235–7.

26. LaPerriere RJ, Wolf JE, Gellin GA. Primary cutaneous plasmacytoma. Arch Dermatol 1973;107:99–100.
cross-ref  pubmed  

27. Bork K, Weigand U. Multiple skin plasmacytomas, increased serum IgA, and lack of bone marrow lesions [German]. Arch Dermatol Res 1975;254:245–52.
cross-ref  pubmed  

28. Fechner RE. Resident’s page. Arch Otolaryngo 1977;103:686–9.

29. Klein M, Grishman E. Single cutaneous plasmacytoma with crystalloid inclusions. Arch Dermatol 1977;113:64–8.
cross-ref  pubmed  

30. Grimard M. Malignant cutaneous plasmacytomas [French, doctoral thesis in Medicine]. Lyon, France: Université de Lyon; 1978.

31. Llamas-Martin R, Postigo-Llorente C, Vanaclocha-Sebastian F, Gil-Martin R, Iglesias-Diez L. Primary cutaneous extramedullary plasmacytoma secreting lambda IgG. Clin Exp Dermatol 1993;18:351–5.
cross-ref  pubmed  

32. Canlas MS, Dillon ML, Loughrin JJ. Primary cutaneous plasmacytoma. Report of a case and review of the literature. Arch Dermatol 1979;115:722–4.
cross-ref  pubmed  

33. Nakamura S, Hoshi K, Onda S, Kamiya S. Primary cutaneous IgA plasmacytoma. J Dermatol 1984;11:482–6.
cross-ref  pubmed  

34. van der Putte SC, de Kreek EJ, Go DM, van Unnik JA. Primary cutaneous lymphoplasmacytoid lymphoma (immunocytoma). Am J Dermatopathol 1984;6:15–24.
cross-ref  pubmed  

35. Wollersheim HCH, Holdrinet RSG, Haanen C. Clinical course and survival in 16 patients with localized plasmacytoma. Scand J Haematol 1984;32:423–8.
cross-ref  pubmed  

36. Gal R, Kolkov Z, Aronof A, Strauss M, Kessler E. Diagnostic use of the immunoperoxidase technique for cutaneous plasma cell lesions. Isr J Med Sci 1985;21:675–8.

37. Foldes C, Vignon-Pennamen MD, Rostoker G, Cottenot F. Cutaneous plasmacytoma [French]. Ann Dermatol Venereol 1988;115:1217–19.

38. Fuji H, Maekawa T, Kanoh T, Ohnaka T, Nishida K. An autopsy case of primary cutaneous plasmacytoma [Japanese]. Rinsho Ketsueki 1989;30:256–61.

39. Muller RP, Krausse S, Rahlf G. Primary cutaneous plasmacytoma. A case report and review of the literature [German]. Hautarzt 1990;41:232–5.

40. Torne R, Su WP, Winkelmann RK, Smolle J, Kerl H. Clinicopathologic study of cutaneous plasmacytoma. Int J Dermatol 1990;29:562–6.
cross-ref  pubmed  

41. Tsuboi R, Morioka R, Yaguchi H, Shimokawa R, Inaba M, Ogawa H. Primary cutaneous plasmacytoma: treatment with intralesional tumour necrosis factor-alpha. Br J Dermatol 1992;126:395–7.
cross-ref  pubmed  

42. Walker E, Robertson AG, Boorman JG, McNicol AM. Primary cutaneous plasmacytoma: the use of in situ hybridization to detect monoclonal immunoglobulin light-chain mrna. Histopathology 1992;20:135–8.
cross-ref  pubmed  

43. Schmitz L, Simrell CR, Thorning D. Multiple plasmacytomas in skin. Harbinger of aggressive B-immunocytic malignancy. Arch Pathol Lab Med 1993;117:214–16.

44. Kwong YL, Ng WK. Different guises of plasmacytoma—from skin to bone. J Clin Pathol 1994;47:951–3.
cross-ref  pubmed  pmc  

45. Pizarro A, Gamallo C, Sanchez-Munoz JF, et al. Extramedullary plasmacytoma and aids-related Kaposi’s sarcoma. J Am Acad Dermatol 1994;30:797–800.
cross-ref  pubmed  

46. Wong KF, Chan JK, Li LP, Yau TK, Lee AW. Primary cutaneous plasmacytoma—report of two cases and review of the literature. Am J Dermatopathol 1994;16:392–7.
cross-ref  pubmed  

47. Jubert C, Cosnes A, Wechsler J, Andre P, Revuz J, Bagot M. Anetoderma may reveal cutaneous plasmacytoma and benign cutaneous lymphoid hyperplasia. Arch Dermatol 1995;131:365–6.
cross-ref  pubmed  

48. Raznatovsky IM, Aronson VB, Moshkalova IA, Yastrebov VV, Botvinko EV. Solitary primary plasmacytoma of the skin [Russian]. J Dermatovenerol Cosmetol 1996;1:20.

49. Tüting T, Bork K. Primary plasmacytoma of the skin. J Am Acad Dermatol 1996;34:386–90.
cross-ref  pubmed  

50. Vyas R, Dixit S, Singhal S, Neema JP, Suryanarayan U, Baboo HA. Plasmacytoma of scalp. J Postgrad Med 1996;42:27.

51. Miyamoto T, Kobayashi T, Hagari Y, Mihara M. The value of genotypic analysis in the assessment of cutaneous plasmacytomas. Br J Dermatol 1997;137:418–21.

52. Yamamoto T, Katayama I, Nishioka K. Increased plasma interleukin-6 in cutaneous plasmacytoma: the effect of intralesional steroid therapy. Br J Dermatol 1997;137:631–6.
cross-ref  pubmed  

53. Daskalopoulou D, Galanopoulou A, Statiropoulou P, Papapetrou S, Pandazis I, Markidou S. Cytologically interesting cases of primary skin tumors and tumor-like conditions identified by fine-needle aspiration biopsy. Diagn Cytopathol 1998;19:17–28.
cross-ref  pubmed  

54. Galieni P, Cavo M, Pulsoni A, et al. Clinical outcome of extramedullary plasmacytoma. Haematologica 2000;85:47–51.

55. Turitto G, Tortoriello A, Facchini G, et al. Extramedullary primary cutaneous plasmacytoma. Description of a case [Italian]. Recenti Prog Med 2000;91:507–10.

56. Corazza M, Lombardi A, Strumia R, Cuneo A, Virgili A. Primary cutaneous plasmacytoma on chronic lymphoedema. Eur J Dermatol 2002;12:191–3.

57. Tessari G, Fabbian F, Colato C, et al. Primary cutaneous plasmacytoma after rejection of a transplanted kidney: case report and review of the literature. Int J Hematol 2004;80:361–4.
cross-ref  pubmed  

58. Lou Y, Jin J, Tong X. A patient of extramedullary cutaneous and gingival plasmacytomas. Eur J Haematol 2005;75:171.
cross-ref  pubmed  

59. Ak I, Gülbas Z. Primary cutaneous plasmacytoma presenting with multiple subcutaneous nodules by F-18 fdg imaging. Clin Nucl Med 2007;32:79–81.

60. Dhouib Sellami R, Sassi S, Mrad K, Abess I, Driss M, Ben Romdhane K. Primary cutaneous plasmacytoma [French]. Ann Pathol 2007;27:130–2.
cross-ref  pubmed  

61. Gambichler T, Othlinghaus N, Stucker M, Altmeyer P, Kreuter A. Cutaneous giant plasmacytoma associated with monoclonal gammopathy of unknown significance. Clin Exp Dermatol 2009;34:417–18.
cross-ref  pubmed  

62. Ioannidis O, Kakoutis E, Varnalidis I, et al. Giant cutaneous plasmacytoma of the sacrococcygeal region. J Cutan Med Surg 2010;14:90–4.
cross-ref  pubmed  

63. Arias-Santiago S, Aneiros-Fernandez J, Arrabal-Polo MA, et al. Cutaneous plasmacytoma and leukemia cutis on the penis. Eur J Dermato 2011;21:107–9.

64. Li A, Chen A, Gallagher M, et al. Primary cutaneous plasmacytoma occurring after pacemaker implantation and recurring in scar tissue. Dermatol Online J 2013;19:3.

65. Malissen N, Fabre C, Joujoux JM, et al. Multiple primary cutaneous plasmacytoma [French]. Ann Dermatol Venereol 2014;141:364–8.
cross-ref  pubmed  

66. Uçmak D, Meltem Akkurt Z, Türkçü G, Harman M, Sinan Dal M, Uçmak F. Multiple primary cutaneous plasmacytomas: an unusual presentation. J Cutan Med Surg 2014;18:361–4.
cross-ref  pubmed  

67. Zendri E, Venturi C, Ricci R, Giordano G, De Panfilis G. Primary cutaneous plasmacytoma: a role for a triggering stimulus? Clin Exp Dermatol 2005;30:229–31.
cross-ref  pubmed  

68. Green T, Grant J, Pye R, Marcus R. Multiple primary cutaneous plasmacytomas. Arch Dermatol 1992;128:962–5.
cross-ref  pubmed  

Correspondence to: Alexander Sun, Department of Radiation Oncology, 610 University Avenue, Toronto, Ontario M5G 2M9. E-mail:

(Return to Top)

Current Oncology, VOLUME 23, NUMBER 6, December 2016

Comments on this article

View all comments

Copyright © 2017 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)